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Abstract
Zygomycosis is a difﬁcult to treat and frequently fatal infection affecting immunocompromised and, rarely, immunocompetent patients.
The early diagnosis and immediate initiation of treatment with an antifungal agent in combination with surgical intervention has proved
critical for the favourable outcome of the disease. Few antifungal agents are available for treatment. Amphotericin B (AmB) deoxycho-
late has been the drug of choice for many years and is usually given at high daily doses which can result in renal toxicity. Currently, lipid
formulations of AmB (liposomal AmB (L-AmB), AmB lipid complex (ABLC), AmB colloidal dispersion (ABCD)), mainly L-AmB, rather
than conventional AmB have become the standard therapy. The rationale behind the use of lipid formulations is that they decrease the
nephrotoxicity associated with longterm AmB use. Although there is a developing consensus that high doses of lipid formulations of
AmB should be the antifungal therapy of choice for all patients with zygomycosis, until now there have been no data available with
which to deﬁne the appropriate dose. The duration of therapy remains an unresolved issue, regarding both lipid formulations of AmB
as well as sequential or combination treatments consisting of lipid formulations of AmB with posaconazole, a drug which has now
emerged as a new therapeutic option.
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Introduction
Zygomycosis is an emerging, frequently fatal, fungal infection
in severely immunocompromised patients such as haemato-
poietic stem cell transplant (HSCT) and solid organ trans-
plant (SOT) recipients, leukaemic patients with deep and
prolonged neutropenia, those on corticosteroid therapy,
patients with human immunodeﬁciency virus (HIV) infection,
and patients with diabetes mellitus and ketoacidosis [1–12].
Zygomycosis can also affect immunocompetent patients with
trauma or burns [13–15] and patients with elevated available
serum levels of iron under treatment with deferoxamine
[6,16]. In patients at higher risk, such as those undergoing
allogenenic bone marrow transplantation, the prevalence of
zygomycosis has been described to be as high as 2–3%
[6,17]. Recently, an increased incidence of zygomycosis in
high-risk patients was observed in parallel with the introduc-
tion of newer antifungal agents and especially voriconazole
[6,17–23]. Zygomycosis usually presents clinically as rhinoce-
rebral, pulmonary, cutaneous or disseminated disease which
progresses rapidly [4, 8, 24].
The prognosis for patients with zygomycosis has been
historically poor. However, although mortality can approach
100%, depending on the patient’s underlying disease and the
form of zygomycosis [25], it has been reduced to <50% since
amphotericin B (AmB) became available [4,26], although it
has remained essentially unchanged since the 1960s, when
AmB deoxycholate was introduced [8]. However, the avail-
ability of less toxic lipid formulations has led to recent
reports of an overall survival rate in patients with zygomy-
cosis of up to 85% [27, 28].
Antifungal Therapy with AmB Formulations
Most clinical experience in the antifungal treatment of zygo-
mycosis has concerned AmB formulations. Evidence comes
from case reports and case series describing the outcome of
patients treated with AmB deoxycholate [29–32] and its lipid
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forms, alone or in combination with surgical debridement
[33–40].
Antifungal therapy alone has been used successfully in
cases where surgical intervention was not possible or was
not preferable because of the site of the infection [41–44].
Roden et al. [8] reviewed 929 cases of zygomycosis reported
in the literature until 2004. Of 596 (64%) patients who
received some form of antifungal therapy, 62% survived. Of
these 596 patients, 532 (89%) received AmB deoxycholate
and 116 (19%) received a lipid form of AmB. The survival
rates were 61% for patients treated with AmB deoxycholate,
69% for those treated with lipid formulations of AmB, and
67% for patients treated with an azole, compared with 70%
for those treated with combined antifungal therapy and sur-
gery. Analysis of survival by decade revealed that overall
mortality improved from 84% in the 1950s to 47% in the
1990s. All these studies stress the importance of the combi-
nation of early aggressive surgical excision of the necrotic
lesions, restoration of immune function, and intense therapy
with AmB formulations.
AmB deoxycholate
For many years, treatment with AmB deoxycholate has been
regarded as the reference standard for the treatment of
zygomycosis. Higher doses of AmB seem to be needed for
the successful treatment of this disease, as compared with
other mycoses. Recommended doses of AmB deoxycholate
have been 1–1.5 mg/kg/day [3,37]. Although AmB deoxycho-
late is effective in the treatment of zygomycosis and is
inexpensive, it is toxic, causing infusion-related symptoms
and nephrotoxicity; it also penetrates the blood–brain
barrier poorly. Conventional AmB, despite being a broad-
spectrum fungicidal agent with little intrinsic or acquired
resistance, is limited in by its serious toxicities and lack of an
oral formulation for systemic therapy. Renal toxicity is a
major side-effect of the conventional drug [45,46].
Lipid formulations of AmB
Formulations using a lipid carrier have signiﬁcantly improved
AmB tolerability. In recent years, three lipid formulations of
AmB have become available: liposomal AmB (L-AmB); AmB
lipid complex (ABLC), and AmB colloidal dispersion (ABCD).
Lipid formulations of AmB are clearly less nephrotoxic and
safer than AmB deoxycholate. This advantage of lipid formu-
lations allows for increased daily dosage and long-term
administration with fewer infusion-associated side-effects,
while still achieving high tissue concentrations in the lungs,
liver and spleen [47,48]. Their efﬁcacy appears to be compa-
rable to or better than that of AmB deoxycholate [8]. These
lipid formulations of AmB have been used in the treatment
of zygomycosis with consistently successful outcomes
[43,44,49–53] and therefore are considered as drugs of choice
for this disease [52]. AmB lipid formulations should be used at
a dose starting at 3–5 mg/kg/day, although higher doses will
be needed occasionally. Doses in the range of 10–15 mg/kg/
day have sometimes been used, but the optimal dose remains
unclear. However, the use of increased dosing for lipid-based
AmB increases costs enormously [53]. The duration of
antifungal treatment should be determined on an individual
basis, but therapy usually continues for at least 6–8 weeks.
The optimal duration of AmB formulations for the treatment
for zygomycosis remains an unresolved issue [54].
Liposomal AmB (L-AmB; Ambisome). The ﬁrst case of success-
ful treatment of rhinocerebral zygomycosis with L-AmB was
reported by Fisher et al. [55]. Since then, several other case
reports and reviews [9,34,39,49,56–65] have supported the
use of L-AmB as a ﬁrst-line agent for the treatment of zygo-
mycosis. A review of 120 cases of zygomycosis in patients
with haematological malignancies found a survival rate of
67% (10/16) in patients treated with L-AmB compared with
39% (24/62) in those treated with AmB deoxycholate
(p =0.02) [64]. In an Italian retrospective study of 59 patients
with haematological malignancies and proven or probable
zygomycosis, the response rate was 23% (9/39) in patients
who received AmB deoxycholate compared with 58% (7/12)
in those treated with L-AmB [9]. Within a pooled efﬁcacy
analysis of cases with invasive ﬁlamentous fungal infections
treated with L-AmB, there was a favourable response in ﬁve
of six (83%) patients with zygomycosis [65].
In a murine model of disseminated Rhizopus oryzae infec-
tion in mice with diabetic ketoacidosis, high-dose L-AmB
(15 mg/kg/day) was considerably more effective than AmB
deoxycholate (1 mg/kg/day), nearly doubling the survival rate
[66]. Although the optimal dose and duration of treatment
with L-AmB has not been established and the recommended
dose for other invasive fungal infections is 3 mg/kg, in most
cases it has been used in doses of 5–15 mg/kg/day and for a
duration of £6 months [39,51,53,57,61–63,67–70].
Amphotericin B lipid complex (ABLC; Abelcet). Amphotericin B
lipid complex is another lipid form of AmB that was devel-
oped to reduce nephrotoxicity. ABLC may be beneﬁcial in
the treatment of difﬁcult-to-treat invasive fungal infections,
and it has been reported to be an effective antifungal treat-
ment in many invasive and refractory non-Aspergillus mould
infections, such as zygomycosis [71].
Several case reports have shown successful outcomes
after treatment of zygomycosis with ABLC alone or in com-
bination with surgery [35,72,73]. Strasser et al. [72]
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described the ﬁrst well-documented case of a patient with
rhinocerebral mucormycosis treated successfully with ABLC.
The efﬁcacy and renal safety of ABLC in the treatment of
64 immunocompromised patients with zygomycosis, on the
basis of a search of the Collaborative Exchange of Antifungal
Research (CLEAR) database, were described by Larkin and
Montero [74]. The median daily ABLC dose was 4.8 mg/kg
(range 0.9–12.6 mg/kg), and the median duration of therapy
was 16 days. The overall favourable clinical response to
ABLC amounted to 72% (46/64 patients), with 13% (8/64) of
patients with disseminated disease described as cured, 39%
(25/64) as improved and 20% (13/64) as stable). Of 35
patients who received ABLC as second-line therapy, 24
(69%) made a favourable response. Eight (80%) of ten
patients who received ABLC as ﬁrst-line therapy and 14
(78%) of 18 patients with pre-existing renal disease
responded favourably to therapy with ABLC [74].
In another large study with 556 patients who were refrac-
tory to or intolerant of antifungal therapy and who were
treated with ABLC, 71% of 24 patients with zygomycosis had
a complete or partial response [35]. Further, Forrest and
Mankes [75] reviewed the outcome of six diabetic renal
transplant recipients with biopsy-proven invasive zygomycosis
who received ABLC. Three of six patients survived after
prolonged courses of ABLC at 10 mg/kg/day in combination
with surgical debridement. All survivors lost graft function
during the course of their therapy.
Amphotericin B colloidal dispersion (ABCD; Amphocil, Ampho-
tec). The data in the English language literature regarding
treatment of zygomycosis with ABCD are limited. The ﬁrst
detailed clinical description of the treatment of zygomycosis
with ABCD was by Moses et al. [76]. In this study, three
patients with life-threatening rhinocerebral zygomycosis were
treated with ABCD. All patients had high serum creatinine
levels as a result of prior treatment with AmB; these levels
reverted to normal during treatment with ABCD. Two
patients with diabetes mellitus were cured after receiving a
combination of surgery and ABCD therapy. The third
patient, who had myelodysplastic syndrome, had an initial
good response with cure of the fungal infection; however, he
eventually died of his primary illness. Another six patients
with zygomycosis were included in a review of bone marrow
transplant recipients treated with ABCD [77]. Eight of 19
(42%) patients with invasive fungal infections other than
Candida and Aspergillus, including the six cases of zygomyco-
sis, responded. In a review [48] of 21 patients with invasive
zygomycosis treated with ABCD from ﬁve phase I and phase
II studies, 12 of 20 (60%) patients responded. These patients,
all of whom had undergone bone marrow or organ trans-
plantation, or had haematological malignancies or diabetes,
were given ABCD on the basis of pre-existing renal insufﬁ-
ciency, development of nephrotoxicity during AmB therapy,
or fungal infection that failed to respond to AmB therapy
combined with surgical debridement. Infection was dissemi-
nated in six patients and localized to the sinuses, lower
respiratory tract or skin in the other patients. ABCD was
given at a mean dose of 4.8 mg/kg per infusion for a mean
duration of 37 days.
Discussion
Because of the relative rarity of zygomycosis, no prospective
comparative studies of different antifungal agents have been
conducted. Therefore, the choice of therapy has been based
on experience, animal model studies [66,78] and in vitro sus-
ceptibility data [79]. Historically, AmB deoxycholate has been
used at relatively high doses of up to 1.5 mg/kg/day [3].
However, the introduction of the less toxic lipid formula-
tions, backed by animal studies and clinical data to support
their use in zygomycosis [27,35,36,62,78,80,81], has led to
their use as primary therapy. The most extensive experience
is with L-AmB and ABLC, whereas ABCD has been used in
fewer cases. Current evidence comes from case reports and
case series describing outcomes in patients treated with
AmB formulations. Based on this clinical experience, L-AmB
has become the therapeutic agent of choice [62,80]. In addi-
tion, pharmacokinetic data [81], animal model data [78], and
retrospective clinical data [9,34–37,39,46,49,52,56–65] all
support the ﬁrst-line use of high-dose L-AmB for zygomyco-
sis, particularly for cases of central nervous system disease,
with ABLC serving as a reasonable second-line agent.
Although doses in the range of 10–15 mg/kg/day have
been used, the optimal dose remains unclear. Several case
reports of patients with zygomycosis document successful
treatment with L-AmB given in doses of 3–15 mg/kg/day.
However, whether the higher doses of L-AmB are preferable
for the treatment of zygomycosis is unknown. Walsh et al.
[82] published a phase I–II study proving that L-AmB, at dos-
ages as high as 15 mg/kg/day, followed non-linear saturation-
like kinetics and was well tolerated and provided effective
therapy for aspergillosis and other ﬁlamentous fungal infec-
tions. By contrast, the obvious conclusion of the AmBiLoad
study [83] was that administration of 10 mg/kg/day L-AmB to
patients with invasive fungal infections does not improve efﬁ-
cacy, but increases toxicity and cost. Early initiation of treat-
ment of zygomycosis is crucial in severely ill patients.
Delayed AmB-based frontline therapy (i.e. initiating treatment
‡6 days after diagnosis) resulted in a two-fold increase in
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mortality at 12 weeks after diagnosis compared with early
treatment (82.9% vs. 48.6%) [84]. A further consideration is
combination antifungal therapy [85]; some case reports have
described successful outcomes using combinations of L-AmB
with either caspofungin or posaconazole in cases where sin-
gle-agent therapy had failed [86,87]. These encouraging
results are supported by animal model data [88] and in vitro
synergy studies [89].
Conclusions
Lipid formulations of AmB appear to have replaced conven-
tional AmB in the treatment of zygomycosis. Until direct
comparisons of the efﬁcacy of L-AmB and ABLC are pub-
lished, deﬁnitive conclusions regarding their relative efﬁcacies
for zygomycosis cannot be made. Based on pharmacokinetic
and animal model data, as well as clinical experience, high
doses of L-AmB can be used as a ﬁrst-line treatment of
zygomycosis, with ABLC serving as a reasonable second-line
agent. The early (<6 days) initiation of treatment after diag-
nosis is crucial for the successful outcome of zygomycosis,
but the optimal duration of treatment is unknown.
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